TP53 and neoplasm: Hence, romidepsin and Ad-CMV-p53 combination proved capable to cause a significant tumor inhibition in vitro and in vivo, thus suggesting that a pre-treatment step of tumor cells with romidepsin may increase the efficiency of adenoviral gene-therapy vectors [212].